192 related articles for article (PubMed ID: 37679565)
41. A COMPASS in the voyage of defining the role of trithorax/MLL-containing complexes: linking leukemogensis to covalent modifications of chromatin.
Tenney K; Shilatifard A
J Cell Biochem; 2005 Jun; 95(3):429-36. PubMed ID: 15786493
[TBL] [Abstract][Full Text] [Related]
42. Functional specificity of CpG DNA-binding CXXC domains in mixed lineage leukemia.
Risner LE; Kuntimaddi A; Lokken AA; Achille NJ; Birch NW; Schoenfelt K; Bushweller JH; Zeleznik-Le NJ
J Biol Chem; 2013 Oct; 288(41):29901-10. PubMed ID: 23990460
[TBL] [Abstract][Full Text] [Related]
43. c-Myb, Menin, GATA-3, and MLL form a dynamic transcription complex that plays a pivotal role in human T helper type 2 cell development.
Nakata Y; Brignier AC; Jin S; Shen Y; Rudnick SI; Sugita M; Gewirtz AM
Blood; 2010 Aug; 116(8):1280-90. PubMed ID: 20484083
[TBL] [Abstract][Full Text] [Related]
44. TGIF1 is a negative regulator of MLL-rearranged acute myeloid leukemia.
Willer A; Jakobsen JS; Ohlsson E; Rapin N; Waage J; Billing M; Bullinger L; Karlsson S; Porse BT
Leukemia; 2015 May; 29(5):1018-31. PubMed ID: 25349154
[TBL] [Abstract][Full Text] [Related]
45. Loss of MLL Induces Epigenetic Dysregulation of Rasgrf1 to Attenuate Kras-Driven Lung Tumorigenesis.
Zhu LY; Yuan JB; Zhang L; He CX; Lin X; Xu B; Jin GH
Cancer Res; 2022 Nov; 82(22):4153-4163. PubMed ID: 36098964
[TBL] [Abstract][Full Text] [Related]
46. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.
Daigle SR; Olhava EJ; Therkelsen CA; Basavapathruni A; Jin L; Boriack-Sjodin PA; Allain CJ; Klaus CR; Raimondi A; Scott MP; Waters NJ; Chesworth R; Moyer MP; Copeland RA; Richon VM; Pollock RM
Blood; 2013 Aug; 122(6):1017-25. PubMed ID: 23801631
[TBL] [Abstract][Full Text] [Related]
47. Distinct pathways affected by menin versus MLL1/MLL2 in MLL-rearranged acute myeloid leukemia.
Chen Y; Jones KL; Anastassiadis K; Kranz A; Stewart AF; Grembecka J; Meyerson M; Ernst P
Exp Hematol; 2019 Jan; 69():37-42. PubMed ID: 30315824
[TBL] [Abstract][Full Text] [Related]
48. Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond.
Chen CW; Armstrong SA
Exp Hematol; 2015 Aug; 43(8):673-84. PubMed ID: 26118503
[TBL] [Abstract][Full Text] [Related]
49. MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele.
Thiel AT; Blessington P; Zou T; Feather D; Wu X; Yan J; Zhang H; Liu Z; Ernst P; Koretzky GA; Hua X
Cancer Cell; 2010 Feb; 17(2):148-59. PubMed ID: 20159607
[TBL] [Abstract][Full Text] [Related]
50. Integrative analysis reveals functional and regulatory roles of H3K79me2 in mediating alternative splicing.
Li T; Liu Q; Garza N; Kornblau S; Jin VX
Genome Med; 2018 Apr; 10(1):30. PubMed ID: 29665865
[TBL] [Abstract][Full Text] [Related]
51. Cooperative gene activation by AF4 and DOT1L drives MLL-rearranged leukemia.
Okuda H; Stanojevic B; Kanai A; Kawamura T; Takahashi S; Matsui H; Takaori-Kondo A; Yokoyama A
J Clin Invest; 2017 May; 127(5):1918-1931. PubMed ID: 28394257
[TBL] [Abstract][Full Text] [Related]
52. CRISPR Gene Editing of Murine Blood Stem and Progenitor Cells Induces MLL-AF9 Chromosomal Translocation and MLL-AF9 Leukaemogenesis.
Sarrou E; Richmond L; Carmody RJ; Gibson B; Keeshan K
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32549410
[TBL] [Abstract][Full Text] [Related]
53. Therapeutic strategies against hDOT1L as a potential drug target in MLL-rearranged leukemias.
Banday S; Farooq Z; Ganai SA; Altaf M
Clin Epigenetics; 2020 May; 12(1):73. PubMed ID: 32450905
[TBL] [Abstract][Full Text] [Related]
54. Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia.
Shi A; Murai MJ; He S; Lund G; Hartley T; Purohit T; Reddy G; Chruszcz M; Grembecka J; Cierpicki T
Blood; 2012 Nov; 120(23):4461-9. PubMed ID: 22936661
[TBL] [Abstract][Full Text] [Related]
55. Transcription control by the ENL YEATS domain in acute leukaemia.
Erb MA; Scott TG; Li BE; Xie H; Paulk J; Seo HS; Souza A; Roberts JM; Dastjerdi S; Buckley DL; Sanjana NE; Shalem O; Nabet B; Zeid R; Offei-Addo NK; Dhe-Paganon S; Zhang F; Orkin SH; Winter GE; Bradner JE
Nature; 2017 Mar; 543(7644):270-274. PubMed ID: 28241139
[TBL] [Abstract][Full Text] [Related]
56. c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-associated leukemogenesis.
Jin S; Zhao H; Yi Y; Nakata Y; Kalota A; Gewirtz AM
J Clin Invest; 2010 Feb; 120(2):593-606. PubMed ID: 20093773
[TBL] [Abstract][Full Text] [Related]
57. DOT1L-mediated H3K79 methylation in chromatin is dispensable for Wnt pathway-specific and other intestinal epithelial functions.
Ho LL; Sinha A; Verzi M; Bernt KM; Armstrong SA; Shivdasani RA
Mol Cell Biol; 2013 May; 33(9):1735-45. PubMed ID: 23428873
[TBL] [Abstract][Full Text] [Related]
58. Bioinformatic Analyses of Broad H3K79me2 Domains in Different Leukemia Cell Line Data Sets.
Sharma P; Sattarifard H; Fatemiyan N; Lakowski TM; Davie JR
Cells; 2022 Sep; 11(18):. PubMed ID: 36139405
[TBL] [Abstract][Full Text] [Related]
59. NUP98-MLL fusion in human acute myeloblastic leukemia.
Kaltenbach S; Soler G; Barin C; Gervais C; Bernard OA; Penard-Lacronique V; Romana SP
Blood; 2010 Sep; 116(13):2332-5. PubMed ID: 20558618
[TBL] [Abstract][Full Text] [Related]
60. Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia.
Geng H; Brennan S; Milne TA; Chen WY; Li Y; Hurtz C; Kweon SM; Zickl L; Shojaee S; Neuberg D; Huang C; Biswas D; Xin Y; Racevskis J; Ketterling RP; Luger SM; Lazarus H; Tallman MS; Rowe JM; Litzow MR; Guzman ML; Allis CD; Roeder RG; Müschen M; Paietta E; Elemento O; Melnick AM
Cancer Discov; 2012 Nov; 2(11):1004-23. PubMed ID: 23107779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
